GEN Exclusives

More »

GEN News Highlights

Back to Item »

Endotis and Catalent Ink Pact to Develop Anticoagulant

Synthetic oligosaccharide that is an indirect factor Xa inhibitor is expected to enter Phase I next year.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »